158 related articles for article (PubMed ID: 37971139)
21. Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda system for reporting thyroid cytopathology.
Na DG; Kim JH; Sung JY; Baek JH; Jung KC; Lee H; Yoo H
Thyroid; 2012 May; 22(5):468-75. PubMed ID: 22304417
[TBL] [Abstract][Full Text] [Related]
22. The 2023 Bethesda System for reporting thyroid cytopathology.
Ali SZ; Baloch ZW; Cochand-Priollet B; Schmitt FC; Vielh P; VanderLaan PA
J Am Soc Cytopathol; 2023; 12(5):319-325. PubMed ID: 37438235
[TBL] [Abstract][Full Text] [Related]
23. Cytological Diagnoses Associated with Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features According to the Bethesda System for Reporting Thyroid Cytopathology: A Systematic Review and Meta-Analysis.
Bongiovanni M; Giovanella L; Romanelli F; Trimboli P
Thyroid; 2019 Feb; 29(2):222-228. PubMed ID: 30426887
[TBL] [Abstract][Full Text] [Related]
24. Hürthle cell presence alters the distribution and outcome of categories in the Bethesda system for reporting thyroid cytopathology.
Yazgan A; Balci S; Dincer N; Kiyak G; Tuzun D; Ersoy R; Cakir B; Guler G
Cytopathology; 2014 Jun; 25(3):185-9. PubMed ID: 24024935
[TBL] [Abstract][Full Text] [Related]
25. The 2023 Bethesda System for Reporting Thyroid Cytopathology.
Ali SZ; Baloch ZW; Cochand-Priollet B; Schmitt FC; Vielh P; VanderLaan PA
Thyroid; 2023 Sep; 33(9):1039-1044. PubMed ID: 37427847
[TBL] [Abstract][Full Text] [Related]
26. [Correlation between the Bethesda system for thyroid nodules and post-thyroidectomy histopathological diagnosis].
Kraus-Fischer G; Alvarado-Bachmann R; Rienzo-Madero B; Núñez-García E; Peña MV; Zerrweck-López C
Rev Med Inst Mex Seguro Soc; 2020 Apr; 58(2):114-121. PubMed ID: 34101555
[TBL] [Abstract][Full Text] [Related]
27. The Presence of Hürthle Cells Does Not Increase the Risk of Malignancy in Most Bethesda Categories in Thyroid Fine-Needle Aspirates.
Ren Y; Kyriazidis N; Faquin WC; Soylu S; Kamani D; Saade R; Torchia N; Lubitz C; Davies L; Stathatos N; Stephen AE; Randolph GW
Thyroid; 2020 Mar; 30(3):425-431. PubMed ID: 32013786
[No Abstract] [Full Text] [Related]
28. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology.
Yaprak Bayrak B; Eruyar AT
BMC Endocr Disord; 2020 Apr; 20(1):48. PubMed ID: 32293401
[TBL] [Abstract][Full Text] [Related]
29. Terminology and nomenclature schemes for reporting thyroid cytopathology: An overview.
Collins J; Rossi ED; Chandra A; Ali SZ
Semin Diagn Pathol; 2015 Jul; 32(4):258-63. PubMed ID: 25680862
[TBL] [Abstract][Full Text] [Related]
30. The atypical thyroid fine-needle aspiration: past, present, and future.
Bongiovanni M; Krane JF; Cibas ES; Faquin WC
Cancer Cytopathol; 2012 Apr; 120(2):73-86. PubMed ID: 21751429
[TBL] [Abstract][Full Text] [Related]
31. Eliminating the "Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance" category from the Bethesda System for Reporting Thyroid Cytopathology.
Singh RS; Wang HH
Am J Clin Pathol; 2011 Dec; 136(6):896-902. PubMed ID: 22095375
[TBL] [Abstract][Full Text] [Related]
32. Combining molecular testing and the Bethesda category III:VI ratio for thyroid fine-needle aspirates: A quality-assurance metric for evaluating diagnostic performance in a cytopathology laboratory.
Gokozan HN; Dilcher TL; Alperstein SA; Qiu Y; Mostyka M; Scognamiglio T; Solomon JP; Song W; Rennert H; Beg S; Stern E; Goyal A; Siddiqui MT; Heymann JJ
Cancer Cytopathol; 2022 Apr; 130(4):259-274. PubMed ID: 34962713
[TBL] [Abstract][Full Text] [Related]
33. The Bethesda system for reporting thyroid cytopathology: an institutional experience of the outcome of indeterminate categories.
Onder S; Firat P; Ates D
Cytopathology; 2014 Jun; 25(3):177-84. PubMed ID: 23998291
[TBL] [Abstract][Full Text] [Related]
34. The 2017 Bethesda System for Reporting Thyroid Cytopathology.
Cibas ES; Ali SZ
Thyroid; 2017 Nov; 27(11):1341-1346. PubMed ID: 29091573
[TBL] [Abstract][Full Text] [Related]
35. The use of The Bethesda System for Reporting Thyroid Cytopathology in a Chinese population: An analysis of 13 351 specimens.
Ke J; Jianyong L; Ying L; Genpeng L; Linlin S; Zhihui L; Jinnan L; Xueying S; Yong J; Jingqiang Z
Diagn Cytopathol; 2019 Sep; 47(9):876-880. PubMed ID: 31074206
[TBL] [Abstract][Full Text] [Related]
36. Implementation of the bethesda system for reporting thyroid cytopathology: interobserver concordance and reclassification of previously inconclusive aspirates.
Pathak P; Srivastava R; Singh N; Arora VK; Bhatia A
Diagn Cytopathol; 2014 Nov; 42(11):944-9. PubMed ID: 24692395
[TBL] [Abstract][Full Text] [Related]
37. BRAF V600E mutation and the Bethesda System for Reporting Thyroid Cytopathology of fine-needle aspiration biopsy for distinguishing benign from malignant thyroid nodules.
Sheng D; Yu X; Li H; Zhang M; Chen J
Medicine (Baltimore); 2021 Sep; 100(37):e27167. PubMed ID: 34664843
[TBL] [Abstract][Full Text] [Related]
38. Reporting thyroid FNA before and after implementation of the Bethesda system-one institution's experience.
Brister KJ; Singh RS; Wang HH
Diagn Cytopathol; 2015 Jan; 43(1):28-31. PubMed ID: 24863008
[TBL] [Abstract][Full Text] [Related]
39. The impact of atypia/follicular lesion of undetermined significance and repeat fine-needle aspiration: 5 years before and after implementation of the Bethesda System.
Sullivan PS; Hirschowitz SL; Fung PC; Apple SK
Cancer Cytopathol; 2014 Dec; 122(12):866-72. PubMed ID: 25078420
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Bethesda cytopathology classification to surgical pathology across racial-ethnic groups.
Bresler A; Mehta V; Schiff BA; Smith RV; Khader S; Ramos-Rivera G; Lin J; Libutti SK; Laird AM; Ow TJ
Head Neck; 2019 Jul; 41(7):2340-2345. PubMed ID: 30793405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
